Please enter your username and password below, if you are not yet a member of Oncology Central remember you can register for free.
Already have an account? Login here
Categories // Skin
Research presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II (22–24 June 2020) has demonstrated that Stage III melanoma patients who receive adjuvant immunotherapy have an improved survival benefit compared to patients who did not receive immunotherapy following surgery.
It's completely free
Written ByCaitlin Killen, Future Science Group
Updated 30 June, 2020